US stock anomaly | AbbVie Inc. (ABBV.US) rises 6%, spends $10.9 billion to acquire Apogee

According to the app of Citic Securities, on Monday, AbbVie Inc. (ABBV.US) rose by 6%, reaching $229.62. In terms of news, on June 22, AbbVie signed a final acquisition agreement with Apogee Therapeutics to acquire all outstanding shares of Apogee for $135.11 per share in cash, with a total equity value of approximately $10.9 billion. This acquisition will complement AbbVie's existing immunology product portfolio and accelerate its expansion in the respiratory disease field.